Patents by Inventor Adina Eberth

Adina Eberth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-18 BINDING MOLECULES
    Publication number: 20220098296
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: July 27, 2021
    Publication date: March 31, 2022
    Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
  • IL-18 binding molecules
    Patent number: 11111293
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: September 7, 2021
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 10407496
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: September 10, 2019
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • IL-18 BINDING MOLECULES
    Publication number: 20190085068
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: August 24, 2018
    Publication date: March 21, 2019
    Applicant: NOVARTIS AG
    Inventors: Michael Otto BARDROFF, Barbara BRANNETTI, Emma Michelle CAMPBELL, Beate DIEFENBACH-STREIBER, Adina EBERTH, Christian Carsten Silverster KUNZ, Sylwia MARSHALL, Jean-Michel Rene RONDEAU, Jean-Marc Alfred SCHLAEPPI, Gino Anselmus VAN HEEKE
  • IL-18 binding molecules
    Patent number: 10081677
    Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 25, 2018
    Assignee: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20170260260
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 14, 2017
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • IL-18 binding molecules
    Publication number: 20160376361
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: May 25, 2016
    Publication date: December 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silverster Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • IL-18 binding molecules
    Patent number: 9376489
    Abstract: Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: June 28, 2016
    Assignee: Novartis AG
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20160031975
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: April 28, 2015
    Publication date: February 4, 2016
    Applicant: NOVARTIS AG
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 8883158
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: November 11, 2014
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • IL-18 binding molecules
    Publication number: 20140112915
    Abstract: IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.
    Type: Application
    Filed: September 4, 2013
    Publication date: April 24, 2014
    Inventors: Michael Otto Bardroff, Barbara Brannetti, Emma Michelle Campbell, Beate Diefenbach-Streiber, Adina Eberth, Christian Carsten Silvester Kunz, Sylwia Marshall, Jean-Michel Rene Rondeau, Jean-Marc Alfred Schlaeppi, Gino Anselmus Van Heeke
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20130064836
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 14, 2013
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20130022615
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: June 28, 2012
    Publication date: January 24, 2013
    Inventors: Beate DIEFENBACH-STREIBER, Adina EBERTH, Braydon Charles GUILD, Yong-In KIM, Michael ROGUSKA, Igor SPLAWSKI
  • Compositions and methods for antibodies targeting complement protein C5
    Patent number: 8241628
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski
  • Compositions and Methods for Antibodies Targeting Complement Protein C5
    Publication number: 20100034809
    Abstract: The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 11, 2010
    Inventors: Beate Diefenbach-Streiber, Adina Eberth, Braydon Charles Guild, Yong-In Kim, Michael Roguska, Igor Splawski